Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report

Pop, Samantha R.; Strock, Daniel; Smith, Robert J.

doi:10.1111/dth.15623

Cited by 19 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, some reports showed only partial or no response [ 114 ]. In addition, 4 cases of checkpoint inhibitor-induced BP were treated efficiently with dupilumab, a favorable medication as strong immunosuppression needs to be avoided due to the underlying malignancy [ 121 , 122 , 123 , 124 ]. Two patients with BP presumably triggered by COVID-19 vaccinations were also treated efficiently with dupilumab [ 120 , 125 ].…”

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…7 Dupilumab is not currently approved for the treatment of BP. However, due to the role of Th2-mediated inflammation in the pathogenesis of BP, research initiatives around the world [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] and within China [24][25][26][27] have used dupilumab to treat refractory or moderate to severe BP. We attempted to use dupilumab to treat 11 BP patients whose underlying diseases made conventional treatment ineffective or who had poor responses to conventional treatment, and we achieved positive results.…”

Section: Discussionmentioning

confidence: 99%

Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study

Huang

Fu-qiong

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Objective To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid. Methods From October 2020 to October 2022, the medical records of patients with bullous pemphigoid who were treated with dupilumab in our department were collected retrospectively to analyze the therapeutic effect and changes in laboratory indexes. Results The records of a total of 11 patients with bullous pemphigoid who were treated with dupilumab was reviewed. Within 2 weeks of the treatment, 10 (90.9%) of the 11 patients had complete or substantial control of the disease. The BPDAI scores of the patients decreased from baseline 113 (62, 181) to 37 (6, 130) at 2 weeks (p = .001) and 4 (0, 37) at 12 weeks after treatment (p < .001). In the 11 patients treated with dupilumab, the relief time of pruritus was 0–3 days (0.5, 7) days, and the pruritus was significantly alleviated after 2 weeks (t = 15.925, p < .001). The DLQI score decreased from (25.5 ± 2.5) before treatment, to (11.8 ± 4.4) at 2 weeks (t = 10.764, p < .001) and (2.1 ± 1.9) at 12 weeks (t = 30.038, p < .001). The patients had high eosinophil counts, high serum IgE levels, low serum total protein levels, and abnormal blood coagulation function. The aforementioned indicators gradually returned to normal after treatment. No adverse reactions occurred during the treatment. Conclusion Dupilumab can effectively control the condition of bullous pemphigoid, efficiently relieve pruritus symptoms, and is relatively safe.

show abstract

“…14 Dupilumab has been used off-label for pruritus, prurigo nodularis, and BP unrelated to ICIs and there are ongoing clinical trials studying these potential indications. Dupilumab has also been evaluated in 11 patients with ICI-induced BP [15][16][17][18] and in 2 patients with ICI-induced eczema 19 and was successful in all of them. In our case series, we describe the off-label use of dupilumab to manage cutaneous irAEs.…”

Section: Discussionmentioning

confidence: 99%

Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature

Fournier,

Hirsch,

Spreafico

et al. 2023

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Immune checkpoint inhibitors have revolutionized cancer treatment. They can induce cutaneous immune-related adverse events. One patient with immune-related eczema and two with immune-related bullous pemphigoid were successfully treated with dupilumab. Guidelines recommend the use of systemic steroids to manage moderate-to-severe cutaneous immune-related adverse events. They could potentially interfere with immunotherapy. There is a need to find alternative treatments that are safe in a cancer setting.

show abstract

Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report

Cited by 19 publications

References 10 publications

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study

Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature

Contact Info

Product

Resources

About